Does Aetna (CVS Health) Cover Viagra (Sildenafil)?

How Aetna Classifies Viagra on Its Formulary

Aetna places brand-name Viagra (sildenafil citrate 25 mg, 50 mg, and 100 mg tablets) on Tier 3 or Tier 4 of most commercial formularies, while generic sildenafil sits at Tier 2 on the majority of plans. The practical consequence is a significant cost difference. Tier 4 cost-sharing on a typical Aetna PPO can run $60-$120 per 30-day supply for the generic after the deductible, versus $200 or more for brand Viagra.

Sildenafil was first approved by the FDA in March 1998 [1] following the landmark Goldstein et al. trial published in the New England Journal of Medicine, which enrolled 532 men and showed that sildenafil 100 mg produced erections sufficient for intercourse in 69% of attempts versus 22% with placebo (P<0.001) [2]. That efficacy record is why PDE5 inhibitors became the first-line standard for erectile dysfunction (ED) per American Urological Association guidelines [3].

Aetna's formulary is updated quarterly. Because CVS Health acquired Aetna in 2018, many Aetna commercial members now fill prescriptions through CVS Caremark, the pharmacy benefit manager (PBM) that controls formulary placement. Tier placement for your specific plan is visible at Aetna's drug lookup tool or by calling the member services number on your insurance card.

Generic sildenafil entered the U.S. market in December 2017 after Pfizer's compound patent expired. The FDA's Orange Book confirms multiple approved generic manufacturers [4]. Most Aetna plans updated their formularies within one plan year to move generic sildenafil to Tier 2, which substantially reduced out-of-pocket cost for members. If your prescriber writes "brand medically necessary" on the script, the claim may still adjudicate at the higher brand tier even with a generic available.

Prior Authorization Criteria for Viagra on Aetna Plans

Prior authorization (PA) is required for brand Viagra on virtually all Aetna commercial plans, and some plans extend the PA requirement to higher doses of generic sildenafil (50 mg and 100 mg) as well. Aetna's clinical policy bulletin on PDE5 inhibitors outlines the medical necessity criteria a prescriber must document [5].

To win PA approval, the prescriber's office typically must submit:

1. A confirmed diagnosis of erectile dysfunction (ICD-10 code N52.x or related).
2. Documentation that the ED is not primarily caused by a reversible or untreated condition such as hypogonadism, uncontrolled diabetes, or medication side effects that could be addressed first.
3. Evidence of at least one trial of a lower-cost alternative within the same drug class, or a documented clinical reason why that alternative is contraindicated (see step therapy section below).
4. Confirmation that the patient is not taking nitrates or nitric oxide donors, which are absolute contraindications listed on the FDA label [1].

The FDA label specifies that sildenafil is contraindicated with organic nitrates because the combination can cause severe hypotension [1]. A prescriber who documents active nitrate use will receive a denial regardless of other criteria.

Aetna uses a "moderate-to-high" difficulty rating internally for brand Viagra PA requests because the clinical criteria require documented step therapy, not merely a diagnosis. The PA submission goes through CVS Caremark's clinical review team. Standard review takes up to 15 calendar days; urgent medical necessity review must be completed within 72 hours under federal mental health parity and managed care regulations [6].

The HealthRX clinical team has built a PA submission checklist based on the most common reasons Aetna returns requests for additional information:

• Include the exact ICD-10 code (N52.9 for unspecified ED is accepted; a more specific code such as N52.01 for arterogenic ED strengthens the case).
• Attach lab results showing testosterone levels if the prescriber evaluated hypogonadism as a contributing factor, even if testosterone was normal.
• Name the specific generic PDE5 inhibitor trialed, the dose, the duration, and the reason it was discontinued or is inadequate.
• State the starting date and end date of the step therapy trial in the clinical notes, not just "patient tried sildenafil without benefit."

Missing any of these four items accounts for most incomplete PA submissions, causing administrative delays rather than true clinical denials.

Step Therapy Requirements Before Aetna Approves Viagra

Step therapy is the single biggest barrier for members seeking brand Viagra coverage. Aetna requires a documented, adequate trial of generic sildenafil before approving brand Viagra in the majority of its commercial plan designs [5]. An "adequate trial" generally means at least 4 weeks of use at an effective dose (typically 50 mg or 100 mg taken 30-60 minutes before intercourse, per the FDA-approved dosing range [1]).

Some plan variants also accept tadalafil (Cialis generic) or vardenafil as the step-therapy agent. The key is that the trial must be at a clinically appropriate dose. A patient who tried sildenafil 25 mg once and reported no benefit will not satisfy the step-therapy requirement, because 25 mg is below the standard therapeutic dose for most men [2].

Exceptions to step therapy exist. Aetna's clinical policy recognizes step-therapy exemptions when:

• The patient has a documented contraindication to all available generic PDE5 inhibitors (rare, given shared mechanisms).
• The patient experienced a serious adverse event on the generic, such as sudden vision loss or severe hypotension (adverse events reported in post-marketing surveillance [7]).
• The prescriber documents that a specific formulation difference in the brand product is medically necessary, though this is rarely accepted for a simple tablet formulation.

A 2021 analysis in JAMA Internal Medicine found that step-therapy policies delayed access to clinically appropriate therapy by a median of 3.5 months across multiple drug classes, and that 31% of step-therapy denials were eventually overturned on appeal [8]. That overturning rate matters: it means a well-documented appeal is worth pursuing.

What Aetna Covers Beyond Standard ED: Pulmonary Arterial Hypertension

Sildenafil carries a second FDA-approved indication: pulmonary arterial hypertension (PAH), marketed under the brand name Revatio (sildenafil 20 mg tablets or oral suspension) [1]. Aetna's formulary treats Revatio as a separate product from Viagra and places it on a different tier, typically Tier 2 or Tier 3 for the PAH indication, where PA criteria are also different.

If a member has PAH, the PA pathway is distinct and does not require PDE5 step therapy, because the clinical evidence base for sildenafil in PAH is independent of the ED literature [9]. The Galie et al. trial (SUPER-1, N=278) showed sildenafil 20 mg three times daily improved 6-minute walk distance by a mean of 45 meters versus placebo at 12 weeks (P<0.001) [9]. Aetna's PAH clinical policy aligns with the 2022 ESC/ERS pulmonary hypertension guidelines, which give sildenafil a Class I recommendation for PAH Group 1 [10].

Members should never attempt to substitute Revatio for Viagra to circumvent ED step-therapy requirements. The doses are different (20 mg vs. 25-100 mg), the indications are coded differently, and submitting an off-label claim could be considered insurance fraud.

How to Appeal an Aetna Denial for Viagra

Aetna denials for Viagra follow a two-stage appeal process: first-level internal appeal, then external independent review if the internal appeal fails.

First-Level Internal Appeal

The prescriber or the member submits the appeal within 180 days of the denial notice for most commercial plans (check the denial letter for the exact deadline, as self-funded ERISA plans may have different timelines). The appeal package should include:

• The original PA denial letter (to identify the exact reason for denial).
• A letter of medical necessity from the prescriber, citing specific clinical findings, the patient's documented history, and the relevant literature.
• Any additional clinical notes that were not in the original PA submission.
• Peer-reviewed references supporting the medical necessity, such as the AUA guideline on ED management [3] or trial data [2].

Aetna must complete a standard internal appeal within 30 days for prospective requests or 60 days for post-service claims [6]. Expedited appeal decisions for urgent care must be rendered within 72 hours.

External Independent Review

If the internal appeal is denied, the member has the right to request external review by an independent review organization (IRO) accredited under state law or ERISA. The IRO decision is binding on Aetna under the Affordable Care Act's external review provisions [11]. External review requests must typically be filed within 4 months of the final internal denial.

A 2019 report from the Commonwealth Fund found that members who completed external review for specialty and preferred-brand drugs prevailed approximately 40% of the time [12]. Persistence through both stages is the strongest predictor of a successful outcome when the medical case is well-documented.

Key language to include in an appeal letter:

The AUA's 2018 guideline on erectile dysfunction states: "Oral phosphodiesterase type 5 inhibitors (PDE5i) are recommended as first-line therapy for most men with erectile dysfunction" [3]. If Aetna's denial argues that brand Viagra is not medically necessary when generics exist, the appeal should focus on the specific documented reason the generic failed or is inadequate for this patient, not on the superiority of the brand in general.

Manufacturer Savings Card and Cash-Pay Alternatives

Pfizer offers a savings card for brand Viagra through its manufacturer assistance programs, which can reduce out-of-pocket costs for eligible patients [13]. The critical restriction: manufacturer savings cards cannot be used in combination with any federal or state government insurance program (Medicare, Medicaid, TRICARE) and, under many state laws and insurer contracts, are not stackable with commercial insurance either.

The correct use case for the Pfizer savings card is when a member chooses to pay cash for brand Viagra rather than run it through insurance. In that scenario, the card may bring the cost below the insurance copay. Cash-pay generic sildenafil without insurance runs $15-$50 per month at major pharmacy chains and $10-$20 per month through GoodRx or Mark Cuban's Cost Plus Drugs platform [14].

For many men with Aetna coverage, the math favors using generic sildenafil on insurance (Tier 2, $10-$40 copay after deductible) over pursuing brand Viagra approval unless there is a specific documented reason the generic is inadequate. The FDA confirms that approved generic sildenafil must meet the same bioequivalence standards as the brand [4], so clinical outcomes should be equivalent at the same dose.

Does Aetna Cover Viagra for Weight Loss?

No. Viagra and generic sildenafil have no FDA-approved indication for weight loss [1]. A 2023 animal study published in Nature Medicine suggested that sildenafil-class drugs may influence adipose tissue browning through PDE5 inhibition, generating media interest [15]. That research was conducted in rodent models, has not been replicated in human clinical trials, and does not constitute a clinical indication. Aetna's coverage policies follow FDA-approved labeling and AUA/endocrine society guidelines, neither of which supports sildenafil for weight management.

Any prescriber who submits a PA for sildenafil citing weight loss as the primary indication will receive a denial. Off-label prescribing for weight loss also carries malpractice exposure. Patients interested in evidence-based weight loss pharmacotherapy should ask their prescriber about FDA-approved options such as semaglutide 2.4 mg (Wegovy), which produced 14.9% mean body weight reduction over 68 weeks in STEP-1 (N=1,961) [16].

Aetna Medicare and Medicaid Plans: Different Rules Apply

Medicare Part D plans administered by Aetna operate under different formulary rules than commercial plans. The Medicare Modernization Act of 2003 explicitly excluded "agents when used for the treatment of sexual or erectile dysfunction" from Part D coverage unless the drug is also used for a medically accepted non-exclusion indication (such as PAH) [17]. This means brand Viagra and most generic sildenafil 50 mg/100 mg tablets are excluded from Aetna Medicare Part D coverage for ED in most plan designs.

Aetna Medicaid plans vary by state contract. Most state Medicaid programs follow CMS guidance and do not cover PDE5 inhibitors for ED. Patients on Aetna Medicare or Medicaid should ask specifically about sildenafil 20 mg (Revatio) coverage if they have a PAH diagnosis.

Plan-Specific Variation: Why You Must Verify Your Own Plan

Aetna administers both fully insured plans (where Aetna sets formulary rules) and self-funded ERISA employer plans (where the employer sets benefit rules and Aetna only administers claims). A self-funded employer plan may have chosen to exclude Viagra entirely, or may have chosen to cover it with no PA. Neither outcome is unusual.

The only way to confirm your plan's exact rules is to:

1. Check the Summary of Benefits and Coverage (SBC) document provided at enrollment.
2. Use Aetna's online formulary look-up tool with your specific plan ID.
3. Call the pharmacy benefits number on your insurance card and ask specifically whether "sildenafil 50 mg" and "sildenafil citrate brand Viagra" require PA on your plan.

The American Academy of Family Physicians notes that insurance formulary look-ups, while publicly accessible, may not reflect real-time tier assignments, making direct plan verification essential before prescribing [18].

Timing and Quantity Limits

Aetna, like most PBMs, applies quantity limits to PDE5 inhibitors. The standard limit is 6 tablets per 30-day supply for sildenafil 50 mg and 100 mg on as-needed dosing regimens. Some plans allow 8 tablets per 30 days. Daily-dose protocols (sildenafil 25 mg once daily, an off-label dosing strategy for men who prefer not to time doses) may be handled differently by the pharmacist and may trigger a PA for quantity exceeding the plan limit.

Exceeding quantity limits triggers an automatic pharmacy rejection. The prescriber must submit a PA specifically for the quantity override, documenting why the standard limit is insufficient. A common reason: patients who also use sildenafil for a documented cardiovascular conditioning protocol supervised by a cardiologist, though this remains off-label [19].